Latest news with #cancerprevention
Yahoo
16 hours ago
- Business
- Yahoo
Breast cancer vaccine moving to critical phase
(NewsNation) — Doctors are currently testing a vaccine for breast cancer they say can stop cancerous tumors from forming before they start. Breast cancer is the second-leading cause of cancer death in women younger than 50, according to the American Cancer Society. The number of younger women being diagnosed with the disease has increased 1.5% each year since 2012. The vaccine, being developed by biotech company Anixa Biosciences, is nearing the end of its phase one trials and moving on to round two. Dr. Amit Kumar, the CEO of Anixa, joined NewsNation's 'Elizabeth Vargas Reports' and said women in the trial responded well to the vaccine, and there are no safety concerns with it. How long does it take weight loss drugs to work? 'Our approach is not to try and deal with the underlying cause, our approach is to train the immune system to destroy those cancer cells as they arise,' Kumar said. 'We think that this is going to be a game-changer.' Kumar added that the eventual goal is to prevent cancer entirely, but to also prevent it in women who have already been through cancer and are worried about a recurrence. The vaccine will officially move to phase two of its trials after meetings with the U.S. Food and Drug Administration. Kumar said he hopes the vaccine will be available to women to prevent cancer within the next few years. 'What's better than treating breast cancer is preventing it,' Kumar said. 'If we can do this for breast cancer, we will do it for other cancers, as well.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
CNET
3 days ago
- Health
- CNET
5 Everyday Foods That May Help Protect Against Cancer
A balanced diet plays a major role in ensuring that you stay healthy. But did you know that there is evidence to suggest that certain foods may even reduce your risk of developing cancer? That's right. While there's no miracle food out there, studies show that certain ingredients may offer some protective benefits. We asked doctors and experts which foods have been shown to potentially decrease cancer risk. 1. Berries Berries are rich in antioxidants and flavonoids like anthocyanins, which are anti-inflammatory and can reduce oxidative stress. "These two factors are major drivers of cancer, and berries pack a punch when it comes to reducing those risks," board-certified oncology dietician and cancer survivor Alison Tierney says. A 2005 study in the European Journal of Cancer found that brightly-colored fruits with high anthocyanin levels may be chemopreventive, and could potentially reduce your risk of developing cancer. The phytochemicals in berries alter the gut microbiome to target immune cells to suppress tumor growth that could develop into cancer. In vivo, polyphenols in raspberries and strawberries have been shown to inhibit colon and prostate cancer cell growth in a 2011 review. Antioxidant-rich strawberries also may inhibit cancer cell growth in the liver, regardless of cultivar type and antioxidant level, in a 2003 test-tube study. Black raspberries have been found to slow colorectal cancer tissue growth in 2011 and 2012 cancer research studies. One 2012 rat study found both blueberries and black raspberries may also inhibit estrogen-driven breast cancer tumors. The chemopreventive effects in black raspberry anthocyanins may also prevent esophageal tumors from developing, according to a 2009 cancer prevention research study on rats. The American Institute of Cancer Research recommends a diet filled with a variety of fruits, vegetables, grains and plant-based foods — including blueberries, cranberries, raspberries and strawberries — to help lower cancer risk, as seen in laboratory studies. 2. Soybeans"Soy often gets a bad reputation, but research suggests it is a cancer-fighting powerhouse," Tierney says. Previously, soy plant estrogens (isoflavones) were believed to disrupt hormones, raising breast cancer risk in women. But soy-based foods like tofu, tempeh, edamame and soy milk do not contain enough isoflavones to increase your breast cancer chances, according to the Mayo Clinic. That said, taking concentrated isoflavone supplements could raise your risk if you have a personal or family history of thyroid issues or breast cancer. The American Cancer Society suggests that rat studies in which rats were exposed to high doses of isoflavones from soy may be linked to breast cancer. However, rats don't process soy the same way people do. Human studies, on the other hand, have revealed that soy's estrogen effects either have no effect or reduce breast cancer risk. A 2021 technical review of 417 reports concluded that soyfoods and isoflavones should not be classified as endocrine disruptors. In a 2024 study, participants eating 54 grams of soy products daily had an 11% reduction in cancer risk, while drinking 23 grams of soymilk daily showed a 28% lesser cancer risk. A 2021 meta-analysis of 300,000 Chinese women who enrolled in a study from 2004 to 2008 and had a follow-up in 2016 found that a 10 mg/day soy intake reduced breast cancer risk by 3%. 3. Tomatoes Lycopene is a potent antioxidant found abundantly in tomatoes that could lower one's risk of developing lung, breast and stomach cancers, according to MD Anderson Cancer Center. A 2022 systematic review of 72 animal and human studies found that lycopene regulates inflammatory and oxidative stress processes, influences cell death and suppresses cell division, tumor growth and formation. In a 23-year longitudinal study of men published in 2016, researchers found that men who consumed two or more servings of tomato sauce weekly had a 30% lower risk of developing prostate cancer than those who ate one serving or less per month. These results are similar to a 2022 epidemiologic study review suggesting that increasing tomato-based product intake may reduce the risk of prostate cancer. Lycopene's ability to suppress tumor progression and boost the immune system while reducing inflammation has also shown promise in reducing the risk of lung cancer. Despite being carotenoids, beta-carotene and lycopene differ chemically, with beta-carotene potentially increasing lung cancer risk. Though tomatoes have a high level of lycopene, it's also found in other red, yellow and orange foods like watermelon, peppers, grapefruit, papaya and guava. 4. Green teaIncluding green tea in your diet may also reduce your risk of developing cancer. "Green tea contains bioactives called catechins, specifically EGCG (epigallocatechin-3-gallate), that starve cancer by cutting off their blood supply," Dr. William Li, scientist and author of Eat to Beat Disease, says. "This activity, known as anti-angiogenesis, has been extensively researched." Angiogenesis is a normal and necessary blood vessel formation process during pre- and postnatal growth stages that helps oxygen reach your organs and tissues. But if your cells malfunction and create tumors, angiogenesis can feed the tumors, creating cancer and helping it spread throughout your body. EGCG has powerful anti-inflammatory and antioxidant effects, which "brings promising results in the prevention of breast, lung, prostate, stomach and pancreatic cancers. A 2012 Nutrients study found EGCG to be the most effective chemopreventive polyphenol in green tea. Over a 30-year study, EGCG in green tea has been shown to delay the onset of cancer and reduce your chances of getting a cancer diagnosis. According to AICR, studies where green tea has been shown to reduce the risk of cancer typically involve a large amount of tea consumption daily, from three to six cups. A 2018 analysis found that drinking more than 10 cups may lower your risk of the following cancers: colorectal, liver, lung and stomach. 5. Cruciferous vegetables Cruciferous vegetables such as broccoli, Brussels sprouts, cauliflower, kale, bok choy and cabbage contain a powerful antioxidant, sulforaphane, that has anti-inflammatory properties and fights against oxidative stress, a factor that can lead to cancer. "Sulforaphane has been shown to not only stop the growth of particular cancer cells but also encourage apoptosis (programmed cell death)," Dr. Courtney Scott, medical director of Momentous Recovery Group in Los Angeles, says. "Its functionality lies in activating specific enzymes that neutralize toxins in the human body, thus reducing the probability of DNA impairment that may stimulate cancer. These have been noted for breast, prostate and colon cancers specifically." A 2000 case-control study found that men who ate a large amount of cruciferous vegetables had a lower risk of prostate cancer. Premenopausal women in a 2008 epidemiological study who consumed cruciferous vegetables (broccoli in particular) regularly were found to have a marginally lower risk of breast cancer. A more recent 2022 study found another compound in cruciferous vegetables, indole-3-carbinol (I3C), frees tumor-suppressing genes to allow them to attack tumor cells and kill them off before they can grow into cancer and spread throughout the body. However, the study was done on lab mice, with humans needing to eat an equivalent amount of over six pounds of broccoli per day to get the same effects. The bottom line Eating a diet rich in fruits, vegetables, green tea and other vitamin-packed foods can nourish your body, allowing you to live a healthy and active life. It may also build your immune response so your body is ready to fight off cancer cells before they can grow and develop into diagnosable cancer. Making foods such as berries, soybeans, tomatoes, cruciferous vegetables and drinks like green tea a regular part of your diet has been shown to potentially provide your body with the right chemicals to reduce your risk of cancer.
Associated Press
4 days ago
- Business
- Associated Press
Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes
NEW YORK, May 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ('Lucid' or the 'Company'), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as part of their 2025 annual reconstitution, according to a preliminary list of additions posted by FTSE Russell on May 23, 2025. 'We are pleased that Lucid is joining these important market indices, which serve as leading benchmarks for institutional investors and as the basis for numerous index-linked financial products,' said Dennis McGrath, Lucid's Chief Financial Officer. 'This important milestone is a testament to the significant progress Lucid has made in enhancing shareholder value over the past year. We are confident that it will increase our visibility and access to a broader range of institutional investors.' The broad-market Russell 3000 Index includes the largest 3,000 U.S. public companies by market capitalization. The Russell 2000 Index is a subset of the broader Russell 3000 Index limited to small-cap companies. The indexes are reconstituted annually by re-ranking companies based on total market capitalization as of the reconstitution rank date, which was April 30, 2025, this year. Index membership remains in place for one year and results in automatic inclusion in the relevant growth and value style indexes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to FTSE Russell, approximately $10.6 trillion in assets are benchmarked against the Russell U.S. Indexes. For more information on the Russell 2000® and Russell 3000® Indexes and the Russell indexes reconstitution, visit the 'Russell Reconstitution' section on the FTSE Russell website. About Lucid Diagnostics Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients. For more information about Lucid, please visit and for more information about its parent company PAVmed, please visit About FTSE Russell FTSE Russell is a leading global provider of benchmarking, analytics, and data solutions for investors, giving them a precise view of the market relevant to their investment process. FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Forward-Looking Statements This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of Lucid's management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of Lucid's common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance Lucid's products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from Lucid's clinical and preclinical studies; whether and when Lucid's products are cleared by regulatory authorities; market acceptance of Lucid's products once cleared and commercialized; Lucid's ability to raise additional funding as needed; and other competitive developments. In addition, Lucid continues to monitor the COVID-19 pandemic and the pandemic's impact on Lucid's businesses. These factors are difficult or impossible to predict accurately and many of them are beyond Lucid's control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect Lucid's future operations, see Part I, Item 1A, 'Risk Factors,' in Lucid's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, 'Risk Factors' in any Quarterly Report on Form 10-Q filed by Lucid Diagnostics after its most recent Annual Report. Lucid disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. View original content to download multimedia: SOURCE Lucid Diagnostics
Yahoo
24-05-2025
- Health
- Yahoo
USA Health Institute presents at National HPV Conference
MOBILE, Ala. (WKRG) — The University of South Alabama's Frederick P. Whiddon College of Medicine presented a poster at the 2025 National HPV Conference held in Indianapolis, Indiana, along with members from the USA Health Mitchell Cancer Institute's Cancer Control and Prevention team. Earthquake recorded 70 miles off the coast of Gulf Shores According to a USA Health news release, the conference gathered healthcare professionals from across the U.S. to discuss human papillomavirus prevention. Representing USA Health Institute at the event were Casey Daniel, Ph.D., MPH, USA Health Director of Epidemiology and Public Health; research assistant Alyssa Lee, MPH; and medical students Grace Sekaya and Destyni Newson from the Primary Care Pathway Scholars Program at Whiddon College of Medicine. 'Attending the National HPV Conference allowed us to engage with leading experts in the field, share our research, and contribute to the growing body of knowledge on HPV vaccination,' Daniel said. 'It is crucial that we continue to educate and collaborate with others on strategies that will help reduce the burden of HPV-related cancers, particularly in medically underserved areas like ours in South Alabama.' MCI presented a poster titled 'HPV Vaccination Completion and Parental Knowledge, Attitudes, and Intentions at a Medically Underserved Federally Qualified Health Clinic in South Alabama.' The poster emphasized the importance of the HPV vaccination in underserved communities and aimed to gain a better understanding of how parental knowledge, attitudes and intentions affect vaccination rates. Mobile pools and splash pads to open ahead of Memorial Day HPV is a major public health issue that is the most common sexually transmitted infection in the U.S. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Asharq Al-Awsat
23-05-2025
- Health
- Asharq Al-Awsat
Weight-Loss Drugs May Lower Cancer Risk in People with Diabetes, a Study Suggests
Excess body weight can raise the risk of certain cancers, leading researchers to wonder whether blockbuster drugs like Wegovy, Ozempic and Zepbound could play a role in cancer prevention. Now, a study of 170,000 patient records suggests there's a slightly lower risk of obesity-related cancers in US adults with diabetes who took these popular medications compared to those who took another class of diabetes drug not associated with weight loss. This type of study can't prove cause and effect, but the findings hint at a connection worth exploring. More than a dozen cancers are associated with obesity. 'This is a call to scientists and clinical investigators to do more work in this area to really prove or disprove this,' said Dr. Ernest Hawk of MD Anderson Cancer Center in Houston, who was not involved in the study. The findings were released Thursday by the American Society of Clinical Oncology and will be discussed at its annual meeting in Chicago. The study, funded by the National Institutes of Health, was led by Lucas Mavromatis, a medical student at New York University's Grossman School of Medicine. 'Chronic disease and chronic disease prevention are some of my passions,' said Mavromatis, a former research fellow with an NIH training program. GLP-1 receptor agonists are injections used to treat diabetes, and some are also approved to treat obesity. They work by mimicking hormones in the gut and the brain to regulate appetite and feelings of fullness. They don't work for everyone and can produce side effects that include nausea and stomach pain. In the study, researchers analyzed data from 43 US health systems to compare two groups: people with obesity and diabetes who took GLP-1 drugs and other people with the same conditions who took diabetes drugs like sitagliptin. The two groups were equal in size and matched for other characteristics. After four years, those who took GLP-1 drugs had a 7% lower risk of developing an obesity-related cancer and an 8% lower risk of death from any cause compared to those who took the other type of diabetes drug. There were 2,501 new cases of obesity-related cancer in the GLP-1 group compared to 2,671 cases in the other group. The effect was evident in women, but not statistically significant in men. The study couldn't explain that difference, but Mavromatis noted that differences in blood drug concentration, weight loss, metabolism or hormones could be at play.
